Transcript profiling towards personalised medicine in rheumatoid arthritis

Netherlands Journal of Medicine

Volumn 67, Issue 11, 2009, Pages 364-371

  Verweij, C L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Disease subtypes; DNA microarray; Genomics; Molecular profiling; Personalised medicine; Pharmacogenomics; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BETA INTERFERON; BIOLOGICAL MARKER; ETANERCEPT; INFLIXIMAB; RHEUMATOID FACTOR;

ARTHRITIS; CELL HETEROGENEITY; CHRONIC ARTHRITIS; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION; GENOMICS; HUMAN; MESENCHYME CELL; PATHOGENESIS; PHARMACOGENOMICS; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; FORECASTING; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MESODERM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SYNOVIAL FLUID;

EID: 74849127968     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-9.
2. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-6.
3. Bos WH, Boers M, Wolbink G, et al. Arthritis development in prospectively followed arthralgia patients is dependent on anti-citrullinated protein antibody status. Arthritis Rheum. 2008;58(9):S290.
4. Klareskog L, Alfredsson L, Rantapaa-Dahlqvist S, Berglin E, Stolt P, Padyukov L. What precedes development of rheumatoid arthritis? Ann Rheum Dis. 2004;63(suppl 2):ii28-31.
5. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651-75.
6. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29(4):365-71.
7. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11.
8. Van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
9. Zanders ED, Goulden MG, Kennedy TC, Kempsell KE: Analysis of immune system gene expression in small rheumatoid arthritis biopsies using a combination of subtractive hybridization and high-density cDNA arrays. J Immunol Methods. 2000;233:131-40.
10. Devauchelle V, Marion S, Cagnard N, et al. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun. 2004;5:597-608.
11. Nzeusseu TA, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, Lauwerys BR. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:1579-88.
12. Van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun. 2003;4:187-96.
13. Van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003;48:2132-45.
14. Tsubaki T, Arita N, Kawakami T, Shiratsuchi T, et al. Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther. 2005;7:R825-36.
15. Timmer TC, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum. 2007;56:2492-502.
16. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997;151:317-22.
17. Brouty-Boye D, Pottin-Clemenceau C, Doucet C, Jasmin C, Azzarone B. Chemokines and CD40 expression in human fibroblasts. Eur J Immunol. 2000;30:914-9.
18. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SL. Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int. 1998;54:2152-9.
19. Watanabe N, Ando K, Yoshida S, et al. Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun. 2002;294:1121-9.
20. Gallagher J, Howlin J, McCarthy C, et al. Identification of Naf1/ABIN-1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett. 2003;551:8-12.
21. Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor. Inflamm Res. 2005;54:10-6.
22. Kasperkovitz PV, Timmer TC, Smeets TJ, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum. 2005;52:430-41.
23. Aidinis V, Carninci P, Armaka M, et al. Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS Genet. 2005;1:e48.
24. Bovin LF, Rieneck K, Workman C, et al. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. Immunol Lett. 2004;93:217-26.
25. Szodoray P, Alex P, Frank MB, et al. A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:1466-76.
26. Batliwalla FM, Baechler EC, Xiao X, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 2005;6:388-97.
27. Olsen N, Sokka T, Seehorn CL, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004;63:1387-92.
28. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66:1008-14.
29. Pilling D, Akbar AN, Girdlestone J, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol. 1999;29:1041-50.
30. Van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis. 2005;64:1780-2.
31. Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-Navikas S. Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum. 2005;52:3739-48.
32. Van Holten J, Plater-Zyberk C, Tak PP. Interferon-beta for treatment of rheumatoid arthritis? Arthritis Res. 2002;4:346-52.
33. Banchereau J, Pascual V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006;25:383-92.
34. Van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, et al. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of Rheumatoid Arthritis patients. Genes Immun. 2008;9(1):16-22.
35. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932-9.
36. Batliwalla F, Li W, Bienkowska J, et al. Differential peripheral blood gene expression profile of rheumatoid arthritis in response to anti-TNF treatment [abstract]. Arthritis Rheum. 2007;56:S700.
37. Van Baarsen EGM, Wijbrandts CA, Rustenburg F, et al. Pharmacogenomics of anti-TNF treatment in rheumatoid arthritis reveals an active baseline TNF response profile in all patients [abstract]. Arthritis Rheum. 2008;58:S776.
38. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther. 2008;10:R50.
39. Van Baarsen EGM, Wijbrandts CA, Rustenburg F, et al. IFN/TNF Cross-Regulation in vivo during Infliximab Treatment in Rheumatoid Arthritis [abstract]. Arthritis Rheum. 2008;58:S670.
40. Lequerre T, Gauthier-Jauneau AC, Bansard C, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R105.
41. Lindberg J, Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, Lundeberg J. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther. 2006;8:R179.
42. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to anti-TNF{alpha} therapy is related to pre-treatment tissue inflammation levels in Rheumatoid Arthritis patients. Ann Rheum Dis. 2008;67(4):563-6.
43. Van Baarsen EGM, Bos WH, Rustenburg F, et al. Gene expression profiling in autoantibody positive arthralgia patients predicts development of arthritis. Arthritis Rheum. 2009, in press.